Overview Single time-point (STP) dosimetry is gaining traction in the management of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 labeled PSMA (177Lu-PSMA). This approach aims to estimate absorbed radiation doses with a single post-therapy imaging session, typically around 48 hours, reducing imaging burden and resource use compared with traditional multi-time-point (MTP) dosimetry. Here we…